news & views to 3 ng/ml. Data from the control group of the Prostate Cancer Prevention trial show that the probability of detecting disease using a sextant biopsy is 24.7% in men with a serum Psa level between 2.1 and 4.0 ng/ml, and 17% at 1.1-2.0 ng/ml; many cancers detected in such groups are "significant", having a high Gleason score. 7 notably, screening during the ersPC seemed to increase detection rates of low-risk prostate cancer (Gleason score 2-6 and stage t1). so, regardless of the serum Psa threshold that triggers prostate biopsy, it is unlikely to discriminate between clinically relevant and clinically irrelevant prostate cancer, at least on an individual basis. indeed, it was stated recently that there is no lower limit of 'normal' serum Psa level which can definitively exclude the existence of prostate cancer. 8 the ersPC and PlCo investigators must be commended for conducting such well-designed and relevant trials, whichdespite their apparently conflicting interim results-both bring attention to several important points. First, the serum Psa cutoff values that are currently used in screening protocols are unreliable; a value >3 ng/ml is falsely positive for 75% of those screened, whereas there is a high likelihood that one <3 ng/ml will result in a false negative. a screening tool that is superior to Psa is urgently needed, specifically for detection of virulent forms of prostate cancer. second, the criteria for "significant disease" (that is, disease requiring active intervention) need to be revisited, with the aim of reducing overtreatment. in both the ersPC and PlCo study, too many men received aggressive treatment for disease that was unlikely to cause them harm in their lifetime. third, screening for prostate cancer using currently available methods might slightly decrease the number of diseasespecific deaths, but this potential benefit needs to be weighed against the costs to society and patients in terms of quality of life and adverse effects (including the risk of treatment-related death). Patients must be informed accordingly. Finally, until more-sensitive and more-specific screening tools are available that can detect the few cases of prostate cancer with aggressive bio logical potential among the majority of indolent cases, physicians and patients must understand that most diagnosed prostate cancers will never lead to death and that men can only profit from early detection if local and systemic treatment are limited to those patients who truly need it. 
ProSTATe CANCer
Estimating the benefits of PSA screening
Andrew J. Vickers and Hans Lilja
Two groundbreaking trials have this year reported conflicting results as to the benefit of screening for prostate cancer. Careful interpretation in the light of contemporary data is needed to reveal the value of this intervention.
results have recently been published from two large-scale prostate cancer screening trials initiated in the 1990s-the PlCo Cancer screening trial in the us 1 and the ersPC in europe.
2 the PlCo study found no differ ence in prostate cancer mortality between men who were offered annual Psa testing and those who received usual care, whereas the ersPC reported that Psa screening did reduce prostate cancer mortal ity-by about 20% at 9 years. it is important, however, that we interpret the results of these studies correctly. Here we argue that new data on prostate cancer prediction and the outcomes of curative therapy should inform our estimates of the benefits of Psa screening.
it is difficult to have anything but admiration for the investigators of these two trials. they are audacious in scope-the ersPC includes more than 180,000 men aged 50-74 years from 8 countries-and of high methodological rigor. Perhaps above all, one must respect the investigators' willingness to grasp the nettle of testing what has become a widespread technology, despite a lack of clear evidence as to benefit.
the PlCo trial has been criticized on the grounds that over 40% of the participants had undergone a Psa test before the trial, and about half of those in the control arm did so after randomization. our view is that the trial is perfectly sound as long as it is interpreted correctly: it tells us that it is probably not worth telling american men to get a Psa test because they are likely to have already had one, and will continue to do so regardless of our recommendation. in the ersPC, the benefit of screening came at a high cost in terms of the number of men needing to be screened, biopsied and treated to prevent each death. nonetheless, like any study, the ersPC needs to be evaluated in the light of contemporary data-in this case those regarding the ability to predict prostate cancer many years before we recently started to report results from what we believe is the largest and most rigor ous study ever conducted on the longterm prediction of prostate cancer. in brief, over 21,000 swedish men aged 33-50 years who participated in the malmö Preventive Project (mPP), a cardiovascular study, gave blood samples during 1974-1986. we have followed up these men using the swedish Cancer registry to determine prostate cancer outcomes, and retrieved archived blood samples to measure Psa. as the rate of Psa screening in sweden has been very low, our study constitutes a 'natural experiment' to examine the relationship between Psa levels before the age of 50 years and the risk of subsequent prostate cancer.
in our first report, we demonstrated that a single Psa test before the age of 50 years could predict clinically diagnosed prostate cancer occurring up to 25 years later, with an area-under-the-curve of 0.76. 3 Perhaps our key finding concerned the prediction of cancers that were advanced at diagnosis, defined as clinically t3, t4 or metastatic. while for many men prostate cancer is an indolent disease, a t3 or t4 tumor, or a prostate cancer metastasis, is very likely to affect quality of life and survival. we found that 50% of men diagnosed with advanced prostate cancer had Psa levels in the top 10% at age 44-50 years (corresponding to about 1.5 ng/ml or higher); 67% of cancers were in the top 20% of Psa levels (corresponding to about 1.1 ng/ml or higher); and 80% of men diagnosed with advanced prostate cancer had Psa above the median at age 44-50 years (corresponding to about 0.6 ng/ml or higher). 4 our findings are supported by several previous reports suggesting that Psa predicts long-term risk of prostate cancer in unscreened men, although none had the very large number of cases (1,408 to date, 385 with advanced cancer) and long-term follow-up of the mPP study cohort.
these findings have two implications for the interpretation of the Psa screening trials. First, the current trials do not start screening at an early enough age. in ersPCGöteborg, for example, nearly 10% of men were aged 65 years or older. in ersPCrotterdam, the median age of men biopsied in the first round was 66 years, with 25% aged over 70 years. the only way that cancer screening can reduce mortality is by detecting cancers before they become incurable. Yet, as might be expected by the age of study partici pants, many of the cancers detected in the screening arm of the ersPC were already advanced at the time of diagnosis: in ersPCrotterdam, nearly 20% of cancers were clinical stage t3 or t4 in the first round. 5 the mPP cohort demonstrates that we can identify men at increased risk for advanced cancer at early middle-age and up to 25 years before clinical diagnosis. these data suggest that most advanced cancers can be detected with suffi cient lead-time to allow curative therapy. indeed, ersPC-Göteborg and ersPC-rotterdam show that the incidence of advanced cancers was dramati cally reduced during subsequent rounds of screening in comparison with the initial round. 5, 6 second, current screening trials include all men at risk, rather than focusing only on the subgroup at highest risk. the greater the proportion of men at low risk included in a screening trial, the greater the capacity for harm. the Prostate Cancer Prevention trial, 7 in which participants were biopsied irrespective of Psa level, indicates that a very large number of men will have prostate cancer detectable on biopsy at age 62-91 years. the mPP findings suggest that it is feasible to predict at early middleage which men are at increased risk for advanced prostate cancer, and that most men are at very low risk. such men are at substantial risk of harm from screening: increased Psa values associated with benign prostate disease will lead to unnecessary biopsy, and biopsy might discover cancers unlikely to affect a man's survival or quality of life, but which lead to anxiety and treatment-associated morbidity.
Cancer screening can only extend lives if early curative treatment is effective. since the randomized screening trials were designed, data have emerged to suggest that the efficacy of both radiation therapy and surgery can vary greatly. the key determinant of cure for radiation therapy is dose. several randomized trials have demonstrated that increasing the dose of radiation to the prostate from 70 Gy to 79 Gy, something only possible through the use of conformal therapy, decreases 5-year recurrence rates from 21% to 9%. 8 the key determinant of cure from surgery is surgeon experience. we have reported that the probability of being free of cancer 5 years after surgery increases from 82.1% for a patient treated by an inexperi enced surgeon (10 prior cases) to 89.1% for a patient treated by a more experienced surgeon (250 prior cases). 9 For organ-confined diseasethe most common presentation among screened men-the differ ences are more dramatic, with recurrence rates of 14.2% for inexperienced surgeons decreasing to 1% or less for surgeons with 1,000 prior cases. 10 in the mid-1990s, typical radiation therapy doses in europe were often less than 70 Gy, and radical prostat ectomy was relatively rare, entailing that many surgeons had only limited experience of the procedure. thus, many of the patients identified with earlystage prostate cancer in the randomized screening studies are likely to have received suboptimal treatment.
the current trials are not trials of Psa screening per se, but of particular implementations of screening. the ersPC, for example, tests a strategy of starting Psa screening between the ages of 50 and 75 years (with a core age group of 55-69 years) and performing biopsy in men who have Psa levels ≥3 ng/ml. this strategy might do more harm than good if many men had advanced cancers when they entered the trial, or if many unnecessary procedures were conducted on men at low risk. the mPP data suggest an alternative screening strategy: offer a single Psa test at age 45-50 years to all men and then risk-stratify subsequent screening; for example, recommend frequent (yearly) screening for men with Psa levels in the top quartile, offer a 5-yearly Psa retest for men with Psa levels higher than the median but lower than the upper quartile, and offer a single retest at age 60 years for men with Psa levels below the median. men with elevated Psa values might be selected for biopsy on the basis of additional markers, such as free Psa, and possibly also other investi gational measurements in blood, such as other kalli krein markers, or in urinary sediments, such as PCA3.
the problem is that evaluating such a program in a randomized trial would be of
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doubtful feasibility, simply because of the length of trial required. the prostate cancer death rate only starts to accelerate after the age of 65 years, so any trial screening men in their late 40s would take at least 25-30 years to complete. moreover, it is hard to imagine that funding bodies would be ready to initiate additional large trials, considering their ongoing commitment to the ersPC and PlCo study. accordingly, we believe that the only way to evaluate the likely impact of any particular population strategy for Psa screening would be by statistical modeling. in the ersPC, the prostate cancer death rate was 29 per 10,000 in the screening arm and 36 per 10,000 among controls. a straightforward interpretation of this result would be that regular Psa screening starting at age 55-69 years reduces prostate cancer death rates by 7 per 10,000 at 9 years. However, imagine that we examined the data in greater detail and found that 14 of the 29 prostate cancer deaths occurred in men aged over 60 years who were diagnosed with advanced prostate cancer in the first screening round. we might then look at the stage distribution and death rates in subsequent rounds and estimate that, for example, 5 of these 14 deaths could have been prevented had these men had an earlier Psa test. this hypothetical result would indicate that regular Psa screening starting at age 45-50 years would reduce prostate cancer death rates by 12 (7 + 5) per 10,000. naturally, moresophisticated statistical approaches could factor in the effects of changes in treatment patterns or risk stratification, and sensitivity analysis could examine how the model assumptions-such as the number of deaths that could be prevented by earlier screening -affect results.
note that we are not advocating the mentally lazy position of 'medicine changes; therefore, old trials are irrelevant' . rather, we are advocating a careful, systematic, quantitative evaluation of how changes in a trial intervention might modify its effectiveness.
in conclusion, the published trials 1,2 are not trials of prostate cancer screening per se,but of particular approaches to screening in the context of available treatments. Data published since these trials were designed suggest that both the screening approaches and the treatments used in the trials were not as effective as they might be. estimation of the likely effects of prostate cancer screening in a population is better achieved by statistical modeling than by naive application of the effect sizes reported as the principal findings of randomized screening trials.
